Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Santiago - Delayed Quote USD

Biogen Inc. (BIIB.SN)

Compare

140.61

-104.39

(-42.61%)

At close: January 23 at 1:02:45 PM GMT-3

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Biogen Inc.'s ( NASDAQ:BIIB ) recent earnings report didn't offer any surprises, with the shares unchanged over the...

Simply Wall St. 4 days ago

BIIB
$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

CAMBRIDGE, Mass. & BEDFORD, Mass., February 18, 2025--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying

Business Wire 5 days ago

STOK

BIIB
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps an Outperform rating on the shares. The firm’s rating remains Outperform based on its belief that the company will be sold to Biogen (BIIB) at a significant premium, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on SAGE: Sage Therapeutics price target lowere

TipRanks 10 days ago

BIIB

SAGE
Biogen Full Year 2024 Earnings: EPS Misses Expectations

Biogen ( NASDAQ:BIIB ) Full Year 2024 Results Key Financial Results Revenue: US$9.68b (down 1.6% from FY 2023). Net...

Simply Wall St. 10 days ago

BIIB
Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat

Biogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.

Investor's Business Daily 11 days ago

BIIB
Vertiv, Biogen, Super Micro Computer: Market Minute

Yahoo Finance Anchor Brad Smith outlines the top stories on Wall Street on this Market Minute. Vertiv Holdings (VRT) shares drop as its quarterly results topped estimates on the top and bottom lines, while guidance failed to impress investors. Biogen (BIIB) stock slides after the company issued a weak 2025 outlook. Super Micro Computer (SMCI) shares gain on upbeat long-term outlook despite recent challenges. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. This post was written by Naomi Buchanan.

Yahoo Finance Video 11 days ago

SMCI

BIIB

VRT
Biogen expects 2025 profit decline despite strong Q4

American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs. Despite this, the company beat fourth quarter expectations — driven by cost-cutting and new product launches, including its Alzheimer's drug. Watch the video above to hear hosts Brad Smith and Seana Smith discuss Biogen's latest developments. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Josh Lynch

Yahoo Finance Video 11 days ago

BIIB

DX-Y.NYB

DX=F
Genentech eyes lupus market for Gazyva with positive Phase III data readout

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU.

Pharmaceutical Technology 16 days ago

BIIB
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.

Zacks 20 days ago

BIIB
Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain of 23.31%, […]

Insider Monkey 21 days ago

BIIB

^GSPC
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD) in the European Union. In November 2

GlobeNewswire 23 days ago

BIIB
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.

Zacks 24 days ago

BIIB

SAGE

AKRO
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks 25 days ago

BIIB
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

SAGE and AKRO are up this week on regulatory and pipeline updates.

Zacks 25 days ago

SAGE

BIIB

CYTK
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.

Zacks 26 days ago

BIIB

SAGE
Sage rejects Biogen’s $469m takeover bid

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.

Pharmaceutical Technology 26 days ago

SAGE

BIIB
Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks were advancing late Monday afternoon, with the NYSE Health Care Index adding 2.2%

PREMIUM
MT Newswires 27 days ago

BIIB
Sage rebuffs Biogen bid to take it over

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to “maximize” shareholder value.

BioPharma Dive 27 days ago

BIIB
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company

Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. In October, the Massachusetts-based company announced the departure of Chief Financial Officer Kimi Iguchi and laid off over 165 employees as part of a reorganization to focus on the launch of its postpartum depression pill, Zurzuvae. The U.S. Food and Drug Administration approved Zurzuvae, co-developed with Biogen, for postpartum depression in 2023.

Reuters 27 days ago

SAGE

BIIB
Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosing

The approval is supported by data from Phase II Study 201 and its long-term extension.

Pharmaceutical Technology 27 days ago

BIIB

Performance Overview

Return	BIIB.SN	S&P 500
YTD	-42.61%	+2.24%
1-Year	-42.61%	+20.70%
3-Year	-42.61%	+38.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biogen Inc. (BIIB.SN)

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Biogen Full Year 2024 Earnings: EPS Misses Expectations

Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat

Vertiv, Biogen, Super Micro Computer: Market Minute

Biogen expects 2025 profit decline despite strong Q4

Genentech eyes lupus market for Gazyva with positive Phase III data readout

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug

Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

Sage rejects Biogen’s $469m takeover bid

Sector Update: Health Care Stocks Gain Late Afternoon

Sage rebuffs Biogen bid to take it over

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company

Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosing

Performance Overview